Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.32 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3648774 | 0.76 | NPC1 (0.36) | NPC1RAB9AHPGDNCOA1NCOA3 | |
| SCHEMBL28315380 | 0.73 | ALDH1A1 (0.32) | NPC1RAB9AALDH1A1TDP1 | |
| SCHEMBL5043279 | 0.70 | NPC1 (0.36) | NPC1RAB9AHPGDALDH1A1NCOA1 | |
| SCHEMBL28159847 | 0.65 | ALDH1A1 (0.33) | ALDH1A1MAPTTDP1 | |
| SCHEMBL28749627 | 0.64 | NPC1 (0.31) | NPC1RAB9AHPGDALDH1A1 | |
| SCHEMBL31070269 | 0.62 | SLC6A4 (0.36) | NPC1RAB9AHPGDALDH1A1MEN1 | |
| SCHEMBL28159879 | 0.62 | ALDH1A1 (0.31) | ALDH1A1MAPTTDP1 | |
| SCHEMBL27474534 | 0.61 | KCNA4 (0.32) | ALDH1A1TDP1 | |
| SCHEMBL28712291 | 0.60 | KMT2A (0.34) | NPC1RAB9AALDH1A1MEN1MAPT | |
| SCHEMBL27551509 | 0.60 | ALDH1A1 (0.31) | ALDH1A1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8093385-B2 | Leukotriene B4 inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2012-01-10 | — | — | US | disclosed |
| EP-2190808-A1 | LEUKOTRIENE B4 INHIBITORS | F. Hoffmann-Roche AG (CH) | 2010-06-02 | — | — | EP | disclosed |
| WO-2009024492-A1 | LEUKOTRIENE B4 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-02-26 | — | — | WO | disclosed |
| US-20090054466-A1 | Leukotriene B4 Inhibitors | DOMINIQUE ROMYR | 2009-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054466-A1 | Leukotriene B4 Inhibitors | LTB4R2, LTB4R, LTC4S | NPC1 639/4885RAB9A 2954/4885HPGD 77/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.